Brief: Cytodyn Announces FDA Clearance To Proceed With Phase 2 Study Of Leronlimab And Regorafenib
09/09/2019 11:31
Sept 9 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN ANNOUNCES FDA CLEARANCE TO PROCEED WITH PHASE 2
STUDY OF
LERONLIMAB (PRO 140) AND REGORAFENIB AS A COMBINATION THERAPY
FOR METASTATIC COLORECTAL CANCER
Source text for Eikon: ID:nGNX8JwHwN
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer